Skip to main content Skip to section navigation Skip to footer
News & Media Careers Contact
Carrick Therapeutics Limited
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors & Observers
    • Collaborators & Advisors
  • Science
    • Overview
    • Posters & Publications
  • Pipeline
    • Overview
    • CDK7 Inhibitor
    • CDK12/13 Inhibitor
  • Partnering
  • News & Media
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Overview
  • Press Releases
  • IR Calendar
  • In The News
  • Posters & Publications
Dec 19, 2022 9:48am EST

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Dec 01, 2022 8:05am EST

Carrick Therapeutics Closes Series C Financing

Dec 01, 2022 8:00am EST

Carrick Therapeutics Announces $35 Million Investment from Pfizer

Dec 09, 2021 1:00pm EST

Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium

Nov 22, 2021 8:00am EST

Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium

Sep 16, 2021 7:00am EDT

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

Aug 17, 2021 7:10am EDT

Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021

Aug 16, 2021 8:57am EDT

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Aug 16, 2021 7:00am EDT

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Aug 02, 2021 8:30am EDT

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

  • Page 1
  • Page 2
  • Next Pagearrow_forward
rss_feed News RSS
©2023 Carrick Therapeutics Limited. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Visit us on Linkedin Manage Cookie Preferences